| Ytd | -32.25% | |
| 1y | -29.38% |
| Open | 13.84 | Prev Close | 13.87 | Low | 13.40 | High | 13.91 | Mkt Cap | 817.05M |
| Vol | 437.40K | Avg Vol | 702.31K | EPS | -2.09 | P/E | N/A | Forward P/E | -6.94 |
| Beta | 0.20 | Short Ratio | 1.06 | Inst. Own | 37.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 21.34 | 200-d Avg | 22.63 | 1yr Est | 51.82 |
OCS News
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Compan
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potent
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers
Baird analyst Colleen Kusy maintains Oculis Holding (NASDAQ:OCS) with a Outperform and lowers the
Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pri
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to
Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the p
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar
Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pr
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowe
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce